July 14, 2021 05:35 PM EDTUpdated July 16, 10:36 AM

Aducanumab has its approval — now, let citizen-scientists come together to see if it works

Madhav Thambisetty

Adjunct professor of neurology at Johns Hopkins University School of Medicine

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today.

Editor’s Note: Madhav Thambisetty was an advisor on the FDA’s Peripheral and Central Nervous System Drugs advisory committee that voted overwhelmingly not to recommend …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

view job offer post your job now

TRENDING NOW

Aducanumab has its approval — now, let citizen-scientists come together to see if it works

Madhav Thambisetty

Adjunct professor of neurology at Johns Hopkins University School of Medicine

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Merck KGaA will continue to add a tariff surcharge for US customers

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

Sanofi touts $20B investment in US over five years

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Ad­u­canum­ab has its ap­proval — now, let cit­i­zen-sci­en­tists come to­geth­er to see if it works

Madhav Thambisetty

Adjunct professor of neurology at Johns Hopkins University School of Medicine

Sign up to read this article for free.

more like this

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Bio­haven stock sinks on three-month de­lay for neu­ro drug's FDA ap­proval de­ci­sion

Mer­ck KGaA will con­tin­ue to add a tar­iff sur­charge for US cus­tomers

Hen­grui, one of Chi­na's lead­ing biotechs, an­tic­i­pates $1.2B in pro­posed Hong Kong list­ing

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

Sanofi touts $20B in­vest­ment in US over five years

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

Aducanumab has its approval — now, let citizen-scientists come together to see if it works

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Merck KGaA will continue to add a tariff surcharge for US customers

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

Sanofi touts $20B investment in US over five years

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope